Using Neptune Chemistry to Achieve Required Density With Lower Zinc Content; Awarded Three-Well 20k psi Deepwater Project in the Gulf of America With Estimated Start in 2026

SPRING, Texas, June 29, 2026 /PRNewswire/ — TETRA Technologies, Inc. (NYSE: TTI) today announced the introduction of TETRA Neptune Z-Lite, a high-density completion fluid designed for deepwater and high-pressure well applications. The fluid system uses our patented Neptune fluid chemistry and expands the Company’s completion fluids portfolio by offering up to 60% lower zinc-ion concentration than conventional zinc-based fluids while maintaining required density performance. TETRA has been awarded a three-well program for TETRA Neptune Z-Lite for Beacon Offshore Energy’s Gulf of America Shenandoah and Monument projects expected to begin in 2026.

TETRA Neptune Z-Lite reduces zinc-ion concentration, helping limit zinc returns from the wellbore and reduce refinery exposure. Available in densities up to 17.5 ppg, TETRA Neptune Z-Lite is thermally stable, solids-free, and designed to offer lower corrosion potential than conventional zinc brines. The fluid is compatible with most elastomers and formation fluids and can be recycled using standard field equipment.

“TETRA Neptune Z-Lite reflects our focus on fluid chemistry and on delivering differentiated completion fluids technology to meet customer needs in deepwater offshore markets,” said Brady Murphy, president and chief executive officer of TETRA Technologies. “By applying our patented TETRA Neptune and our high-purity zinc bromide chemistries, we are leveraging the advantages of both. The Neptune chemistry improves corrosion performance while lowering zinc concentration, thereby reducing handling requirements across the wellsite, production facilities, and refineries.”

As deepwater developments target increasingly higher-temperature and higher-pressure reservoirs, TETRA Neptune Z-Lite is designed to deliver a lower life cycle well cost, which further strengthens the Company’s position in the growing global deepwater markets.

For more information about TETRA Neptune Z-Lite, click here. 

Company Overview

TETRA Technologies, Inc. is an energy services and solutions company focused on developing environmentally conscious services and solutions that help make people’s lives better. With operations on six continents, the Company’s portfolio consists of Energy Services, Industrial Chemicals, and Critical Minerals. In addition to providing products and services to the oil and gas industry and calcium chloride for diverse applications, TETRA is expanding into the low-carbon energy market with chemistry expertise, key mineral acreage, and global infrastructure, helping to meet the demand for sustainable energy in the twenty-first century. Visit the Company’s website at www.onetetra.com for more information or connect with us on LinkedIn.

Cautionary Statements

This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are identifiable by the use of the following words, the negative of such words, and other similar words: ‘believes’, ‘estimates’, ‘expects’, ‘intends’, ‘projects’, and ‘targets’.” These statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding expected timing of operations; the number of wells expected to be part of the program; the anticipated performance, benefits, and acceptance of the Company’s products and technologies; expected cost and environmental advantages; and the Company’s competitive position and growth opportunities in deepwater and other markets. These forward-looking statements are based on certain assumptions and analyses made by TETRA in light of its experience and its perception of historical trends, current conditions, expected future developments, and other factors it believes are appropriate in the circumstances. Such statements are subject to several risks and uncertainties, many of which are beyond the control of TETRA. Important factors include, among others, that the market may not grow as anticipated, or may decline; the anticipated benefits may not be realized; the actual number of wells may be fewer than currently expected; the program may be delayed, reduced, suspended, or cancelled; the award may not be reduced to a definitive agreement; the products may not perform as expected; and there may be changes in customer capital spending and general economic and industry conditions. These forward-looking statements are based on information available at the time of this release and are subject to a number of risks, uncertainties, and assumptions. For a discussion of these risks, uncertainties, and assumptions, the Company refers you to its filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company does not undertake any obligation to update or revise forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/tetra-technologies-introduces-tetra-neptune-z-lite-deepwater-completions-fluid-302812760.html

SOURCE TETRA Technologies, Inc.

Dario’s best-in-class, consumer-centric chronic care platform, combined now with Beluga’s embedded clinical delivery, extends member engagement to include provider-delivered treatment, lowering costs and expanding value for existing clients while opening large new markets

NEW YORK, June 29, 2026 /PRNewswire/ — DarioHealth Corp. (NASDAQ: DRIO) (the “Company”, “DarioHealth” or “Dario”), a leader in AI-powered digital health solutions, today announced it has entered into a Collaborative Services Agreement (“Agreement”) with Beluga Health, P.A. (“Beluga”), establishing a strategic partnership to deliver a provider-backed, digitally-enabled model for longitudinal care, population health and quality improvement.

By combining Dario’s multi-condition engagement offering with Beluga’s physician-led, 50-state clinical network, the monitoring, detection and treatment of members can happen within one platform. Coaching, AI-driven triage and, with Beluga, clinical treatment across hypertension, diabetes, obesity, behavioral health and musculoskeletal care, are now all integrated in a single, easy-to-manage vendor relationship. When a member’s biometric signal deteriorates, the platform automatically routes patients directly to a prescribing clinician – completing the loop from initial detection all the way through treatment. This whole approach effects an entire category advancement.

This distinguishes Dario from pure engagement vendors. Because chronic conditions can compound over time, Dario’s platform grows with each member, rather than handing them off. Dario’s solution performance is evidence-based: in a study published in JMIR, Dario users had 23% lower hospitalization rates and 26% lower total charges than matched patients receiving usual care. For health plans, the Agreement positions Dario as a quality and revenue performance partner that delivers impact based on where plans are economically incentivized: just a half-star CMS Star Rating gain can be worth roughly $500 per member, and gaps in accurate risk-adjustment documentation can cost more than $1,000 per member per year. Beluga’s white-label medical infrastructure addresses this without Dario building or operating a provider network, thereby expanding contract value per client at high margin.

The Agreement also unlocks new markets. Dario already serves 12 health plans, 3 of them national – a built-in channel to deliver the joint solution to members whose plans adopt it. Beyond existing commercial and Medicare Advantage clients, the integrated architecture opens new growth segments such as state Medicaid programs, federal Rural Health Transformation initiatives and direct health-system partnerships – buyers who increasingly require proof of clinical action, not just engagement. For health systems, that proof is economic, (i.e., keeping complex, comorbid patients and their downstream revenue in network while reducing readmissions that carry direct CMS penalties). For employers, the identification and treatment of chronic-conditions before escalation mitigates risk and limits expensive outcomes before they can happen.

“Health plans and providers don’t need more point solutions – what they need is integrated execution that actually moves the needle on quality, cost and revenue,” said Erez Raphael, Chief Executive Officer of Dario. “We acquire and keep members like a consumer company, manage their conditions as they compound, and now, with Beluga’s clinical depth, turn that engagement into provider-delivered treatment. This is a highly-strategic expansion: our platform already improves outcomes, and Beluga ensures that proven impact now registers where plans are measured – in their Star ratings, risk accuracy and total cost of care. Dario now stands alone in its ability to provide that.”

“Beluga was built to help patients, payers and providers close the loop on value-based care – ensuring that identified health gaps are proactively addressed, documented and reflected in performance,” said Jonah Mink, MD, Co-Founder and Chief Executive Officer of Beluga Health. “Collaborating with Dario allows us to extend that impact upstream, activating members earlier and sustaining engagement in a way that makes high-quality care delivery more impactful, scalable and economically meaningful. Like Dario, we built Beluga as a consumer-first business.  Our companies share the same user-centric DNA, which is exactly what makes this integration work so beautifully.”

An investor briefing is available here. 

About DarioHealth Corp. (NASDAQ: DRIO)

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

Dario’s user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com. 

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected benefits of the collaboration; the anticipated expansion of the Company’s offerings; expected commercial opportunities; anticipated adoption by health plans, providers and other customers; expected impact on quality of care, member engagement and cost savings; and future growth opportunities. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310

Rob Halpern
SVP Marketing
irteam@dariohealth.com

Logo – https://mma.prnewswire.com/media/2866807/5909333/Dario_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/dario-announces-strategic-collaboration-with-beluga-health-to-deliver-provider-backed-integrated-care-at-scale-302812824.html

SOURCE DarioHealth Corp.

Quality Management System Certification Marks Key Regulatory Milestone for Light AI’s Software as a Medical Device Platform

VANCOUVER, BC, June 29, 2026 /CNW/ – Light AI Inc. (“Light AI” or the “Company”) (CBOE CA: ALGO) (FSE: OHC) (OTCQB: OHCFF) an artificial intelligence health technology company developing Software as a Medical Device (“SaMD”) solutions, is pleased to announce that it has successfully completed its Quality Management System”” audit and has been certified as being in conformity with ISO 13485:2016 and the Medical Device Single Audit Program (“MDSAP”) by Intertek.

The MDSAP certification confirms that Light AI’s quality management system meets internationally recognized standards for the design, development, manufacture, and distribution of AI/ML powered devices used to screen, monitor, and assist in the detection of ENT infections management of medical devices and Software as a Medical Device technologies for Canada, the United States and Australia.

Achievement of MDSAP and ISO 13485 certification represents a significant regulatory milestone for the Company and supports its planned regulatory submissions for its QuickScan™ and QuickScan™ Strep A software platforms in Canada.

The certification covers the Company’s quality management processes associated with the development of QuickScan™ software-based medical technologies and establishes the operational framework required to support ongoing regulatory, clinical, and commercialization activities.

“As we continue executing our regulatory strategy, achieving MDSAP and ISO 13485 certification is an important accomplishment for Light AI,” said John R. Luna, Chief Executive Officer of Light AI. “This certification demonstrates our commitment to maintaining a robust medical device quality management system and reflects the significant work completed by our team to align our operations with internationally recognized medical device standards. With this milestone achieved, we are positioned to advance our planned Health Canada regulatory submissions for QuickScan™ Strep A.”

The Company’s QuickScan™ Strep A platform is being developed as Software as a Medical Device solutions intended to support healthcare professionals in the assessment of patients presenting with symptoms consistent with pharyngitis and potential Group A Streptococcus (“Strep A”) infection.

MDSAP allows recognized auditing organizations to conduct a single regulatory audit of a medical device manufacturer’s quality management system that satisfies the requirements of multiple participating regulatory jurisdictions including Canada, Australia and the United States. ISO 13485 is the internationally recognized quality management standard specific to the medical device industry and is widely utilized by regulators and manufacturers globally.

Light AI believes that completion of its MDSAP and ISO 13485 certification establishes an important foundation for future regulatory submissions, including the Company’s planned Health Canada Medical Device License application for QuickScan™ Strep A.

The Company will continue to advance its regulatory, clinical validation, and commercialization activities and expects to provide updates regarding Health Canada submission timing and other key milestones as appropriate.

About Light AI Inc. (CBOE CA: ALGO / FSE: OHC / OTCQB: OHCFF)

Light AI Inc. is a technology company focused on developing artificial intelligence health screening and diagnostic solutions. Light AI QuickScan™ is a technology platform which represents the next generation of patient management: it applies AI algorithms to compatible smart device images, starting with images of Strep A and anticipated expansion with other medical conditions, to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind as its computing platform includes the 4.5 billion smartphones that exist in the world today. Light AI is at the forefront of developing innovative screening and diagnostic solutions aimed at improving healthcare delivery worldwide. Their cutting-edge AI powered technology offers rapid, accurate, and cost-effective screening and diagnostic tools designed to address critical healthcare challenges.

In pre-FDA validation studies, Light AI’s algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (GAS). The algorithm achieved a 96.57% accuracy rate and attained a Negative Predictive Value of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (RHD), which imposes a global economic burden exceeding $1 trillion annually. Light AI’s technology offers a significant advancement in the accurate and timely identification of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI’s approach to applying AI to smart device images can be expanded to other medical conditions, as well as other areas of analysis. Light AI’s vision is to combine the Light AI QuickScan™ software platform with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.

ON BEHALF OF THE COMPANY

“John R. Luna”
Chief Executive Officer
Telephone: 1-(888) 804-9459
Email: jluna@light.ai

Website: https://light.ai/
LinkedIn: LinkedIn/company/Light AI 
X (Formerly Twitter): @lightaihealth

Forward-Looking Information:

This news release contains statements and information that, to the extent that they are not historical fact, constitute “forward-looking information” within the meaning of applicable securities legislation, including statements relating to its anticipated regulatory submissions for the Company’s QuickScan™ and QuickScan™ Strep A software platforms in Canada; the Company’s business plan; and QuickScan™ Strep A platform being developed as Software as a Medical Device solutions and that it will support healthcare professionals in the assessment of patients. Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, but not limited to, statements relating to the Company’s financial performance, business development, results of operations, and those listed in filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.ca). Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking information to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws.

SOURCE Light AI Inc.